A Two-segment Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G11 and CT-G20 in Healthy Volunteers (Part 1 and Part 2) and Open Label, Balanced, Randomized, Two-period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of CT-G20 in Healthy Volunteers (Part 3)
Latest Information Update: 10 Jun 2020
Price :
$35 *
At a glance
- Drugs CT G11 (Primary) ; CT G20 (Primary)
- Indications Cardiovascular disorders; Hypertrophic cardiomyopathy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celltrion
- 07 Jun 2020 Status changed from recruiting to completed.
- 11 Mar 2020 Trial focus, number of participants, outcome measures has been amended.
- 11 Mar 2020 Planned number of patients changed from 48 to 72.